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INTRODUCTION
Corticosteroid treatment of pregnant women at 
risk for preterm delivery enhances fetal lung 
maturity and improves neonatal outcomes(1). 
Despite convincing evidence of these effects, a 
consensus has not been reached about the 
indications for antenatal steroids, and the 
frequency with which they are used remains low 
in some countries(2). The use of antenatal 
corticosteroids for fetal maturation is a rare 
example of technology that yields substantial 
cost in addition to improving health. Because of 
these reasons, National Institutes of Health (NIH) 
Consensus Development Conference on the 
Effect of Corticosteroids for Fetal Maturation on 
Perinatal Outcomes held in March 1994; 
reviewed the scientific basis for the use of 
corticosteroids (CS), short-term and long-term 
potential benefits of the medications, adverse 
effects for the infants and mother, dosage, timing 
and circumstances of administration, and 
associated therapy on treatment outcome (3).
In this article, we review the evidence supporting 
the benefits of CS, controversial issues 
concerning their use, and current practice 
recommendations.
FETAL LUNG M ATURATION
Most infants destined to be delivered at term do 
not have mature lungs until about 36 weeks'
gestation, but only about 50% of Infants born at 
30 weeks' of gestational age have respiratory 
distress syndrome (RDS). The decreased 
incidence of RDS needs to be interpreted within 
the context of maturational phenomena that 
occurs spontaneously in the preterm infant(4). 
After Liggins (1969) observed that fetal CS 
treatments resulted in early lung maturation in 
sheep, numerous clinical trials have documented 
that maternal CS treatments can decrease the 
incidence of RDS (5). In general, corticosteroids 
induce structural maturation of the lungs by 
increasing gas exchange surface area as is 
reflected by lung volume measurements and 
influence structural proteins, such as collagen
(5). The meta-analysis by Crowley found that 
antenatal corticosteroids therapy between 24 
and 34 weeks' gestation resulted in an overall 
approximately 50% in the odds of contracting 
neonatal RDS (6). A secondary analysis, 
stratified by the time interval between trial entry 
and delivery, indicates that babies delivered 
between 24 hours and 7 days after corticosteroid 
administration show a more marked benefit 
(typical odds ratio of RDS, 0.35;95% Cl, 0.26-
0.46). The odds ratios for RDS in infants 
delivered less than 24 hours (0.80; 95% Cl, 0.56-
1.15) or more than 7 days after trial entry (0.63; 
95% Cl, 0.38-1.07) suggest a trend towards a 
treatment effect that does not attain statistical 
significance (6). This data suggests that the 
beneficial effects of corticosteroids may be 
recognized within 24 hours of administration to
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the mother in preterm labor. These results are in 
contrast to earlier recommendations that a 
minimum of 48 hours was needed to observe a 
benefit from steroid use (7).
Corticosteroids not only reduce the incidence of 
RDS in infants exposed to the hormone before 
delivery, but also reduce the severity of 
respiratory distress syndrome . The study by 
Garite et al., which showed lower peak 
ventilatory pressures in betamethasone-treated 
comparecí with untreated infants in spite of 
similar rates of RDS, supports the hypothesis 
that betamethasone use can improve pulmonary 
function without necessarily reducing the overall 
rate of respiratory distress syndrome (8). 
Additional evidence for the respiratory benefit of 
betamethasone use seen by Maher et al., is the 
reduction in the number of days of mechanical 
ventilation for those infants born between 24 and 
31 weeks gestation who received antenatal 
betamethasone therapy compared with those 
who did not (9).
Recent studies have demonstrated that there 
seems to be a synergistic response between 
antenatal steroids and surfactant use in the 
treatment of respiratory distress syndrome . 
Exogenous surfactant treatment also reduces the 
severity of RDS and increases the survival of 
very low birth weight infants (10, 11). Andrews et 
al., found that the outcomes of neonates who 
receive both corticosteroids and surfactant are 
improved compared with those neonates who 
receive only one of the treatments (12).
NONPULMONARY BENEFITS TO  THE 
NEWBORN FROM PRENATAL STEROID 
TREATMENT
Intraventricular Hemorrhage:
One of the principal benefits of corticosteroids is 
the protective effect against intraventricular 
hemorrhage. Howie and Liggins reported that 
steroid treatment reduced the incidence of 
intraventricular hemorrhage (IVH) (13). In 1990 
Crowley et al., while performing a meta-analysis 
of controlled trials evaluating the effect of 
corticosteroids before preterm delivery, noted 
that antenatal corticosteroid administration 
reduced the risk of neonatal intracranial 
hemorrhage in preterm neonates (1). Secondary
analysis of recent trials evaluating the impact of 
neonatal corticosteroid administration on 
neonatal RDS has also revealed a reduction in 
the incidence of IVH (14).
Shankaran et al. recently evaluated prenatal and 
perinatal risk and protective factors for grade III 
and IV IVH in large cohort of singleton low birth 
weight infants (15). They found that a complete 
24h course of corticosteroids was associated 
with an odds ratio of grade lll-IV IVH of 0.39 and 
with a treatment course of <24h, the odds ratio 
was 0.78. Recently, Kari et al demonstrated that 
the incidence of IVH was 28% in the placebo 
compared with 10.4% in the steroid treatment 
group (14). Ment et al reported that corticosteroid 
use was associated with a 40% decrease in the 
incidence of IVH (16). Garite et al. performing a 
randomized, placebo-controlled trial of 
betamethasone for the prevention of RDS at 24 
to 28 weeks' gestation noted a reduction in 
grades III and IV IVH in infants born to women 
who received antenatal steroid therapy (8).
Braks et al. using an animal model, showed that 
if steroids were administered before a hypoxic 
insult, the resulting cerebral infarct was smaller 
than that which occurred in untreated animals. 
Corticosteroids may also protect the brain of the 
preterm infant from hypoxic damage (17).
Circulatory Effects and Patent Ductus 
Arteriosus (PDA):
Corticosteroid treatment improves circulatory 
stability. The trial by Kari et al. demonstrated that 
mean arterial pressures were higher in 
corticosteriod exposed neonates (14) and Moise 
et al. reported that antenatal steroids reduce the 
need for blood pressure support in the preterm 
infant, and that the treated infants had more 
stable mean arterial blood pressures than 
untreated ones (18).
The overall frequency of PDA is reduced in low 
birth weight infants following prenatal maternal 
corticosteroid treatment. In neonates weighing 
less than 2 kg, Waffarin and associates noted 
reduction in the frequency of PDA from 44% to 
6.5% with steroid treatment (19). Similarly 
Clyman and associates noted a reduction in PDA 
frequency from 34% to 18% in steroid-treated 
neonates weighing 500 to 1500 g(20). Clyman 
investigated a potential explanation for fewer
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PDA using vascular rings from the PDA of lambs 
exposed to hydrocortisone in utero compared 
with those of control lambs. The rings were 
obtained from animals 48 hours after steroid 
treatment. PDA rings from the steroid-treated 
fetuses were three times less sensitive to 
prostagland E2 relaxation than those from control 
fetuses (21). However, a recent retrospective 
study by Andrews et al found that a partial course 
of corticosteroid was associated with a slight 
increase in the incidence of PDA (12).
Necrotizing Enterocolitis (NEC):
The risk of NEC is reduced following prenatal 
corticosteroid treatment. A prospective placebo- 
controlled trial confirmed these observations(22). 
In that trial, prenatal betamethasone reduced the 
frequency of NEC to 3.4% compared with 14.4% 
in the control group. The postnatal group in this 
study involved randomized treatment with 
dexamethasone or placebo for infants in the 
prenatal placebo treatment group. In this portion 
of the study, postnatal dexamethasone treatment 
reduced the frequency of NEC to 6.9% compared 
with 14.4%. Each of the steroid-exposed groups, 
both prenatally and postnatally, had significantly 
reduced frequencies of NEC compared with 
groups not treated with steroids (22).
Neonatal Mortality:
Antenatal maternal administration of 
corticosteroids was first shown to decrease the 
neonatal mortality rate in 1972 (13). This finding 
has since been confirmed, both in single and 
multiple center trials. In 1990 Crowley et al. used 
meta-analytic techniques to evaluate 12 
randomized controlled trials. They showed that 
corticosteroid therapy significantly reduced the 
risk of neonatal mortality, with an odds ratio of
0.61 (0.49 to 0.78) (1). Atkinson et al found 
that steroid use was associated with a 50% 
reduction in the odds of neonatal death (23). 
Other studies also have reported similar results
(24).
Studying the long term outcome of these infants 
is important. Goldenberg et al. have reported that 
infants who received antenatal steroids were less 
likely to be suffering from major neurologic 
handicap at 1 year of age when compared with 
an untreated group (25). In fact, long-term follow­
up of the patients reported orginally by Liggins 
and Howie revealed greater gains in height and
weight among females orginally exposed to 
betamethasone (13). In addition, no differences 
were found between male and female babies 
upon neurologic and ophtalmologie examination 
(13, 26).
Other Controversies:
The most controversial recommendation made 
by the National Institutes of Health (NIH) 
Consensus Conference concerned the use of 
corticosteroids in women with preterm premature 
rupture of membranes (PPROM) (3). The 
rationale for this recommendation was that even 
in pregnancies complicated by PPROM, the 
incidence of IVH is lower in neonates exposed to 
antenatal steroids when compared with 
nonexposed infants (23).
The meta-analysis by Ohlsson found that there 
was a significant decrease in the incidence of 
respiratory distress syndrome in infants exposed 
to antenatal steroids in pregnancies complicated 
by PPROM(27). The potential benefits of 
corticosteriods must be compared with the 
possible complications when used in 
pregnancies with PPROM. The Crowley meta­
analysis did not find a significant increase in 
neonatal infection after corticosteroid treatment 
in pregnancies with PPROM (6).
The other question concerning corticosteroid use 
is related to repeat dosing of antenatal steroids if 
the mother remains pregnant 7 days after the first 
steroid treatment but is still at risk of having a 
preterm delivery. A recent retrospective review of 
patients who did or did not receive doses of 
corticosteroids found no difference in the 
incidence of RDS between the two groups (28). 
Also, Bradley et al. reported a case of neonatal 
Cushingoid Syndrome with hypothalamic- 
pituitary-adrenal axis suppression following 
maternal treatment with seven courses of 
betamethasone (29). For these reasons, until a 
prospective trial demonstrates the benefit of 
repeated dosing with corticosteroids, this 
strategy cannot be recommended.
CONCLUSION
For the 27 years since the first clinical reports of 
prenatal corticosteroid treatment to enhance fetal 
lung maturation, this treatment has been studied
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in thousands of preterm newborns. 
Corticosteroids promote the maturation of all 
organ systems, stabilization of arterial blood 
pressure and acceleration of the maturation of 
neuronal cells and germinal matrix vessels may 
contribute to their protective effects as well as 
increased lung maturation and decreased 
severity of respiratory distress syndrome . No 
immediate or long-term adverse effects have 
been demonstrated for the newborn or fetus. 
With PROM, mothers may have an increased risk 
of endometritis without a clear increase in 
overall frequency of infection, at the same 
time steroids significantly decrease the 
frequency of respiratory distress syndrome in 
newborns.
Although numerous randomized controlled trials 
had shown corticosteroids to reduce neonatal 
morbidity and mortality, only about 20% of the 
mothers of preterm infants were treated with this 
hormone before delivery. The NIH Consensus 
Conference recommended that mothers at risk of 
preterm delivery between 24 and 34 weeks' 
gestation should receive corticosteroids unless 
delivery was imminent. The conference also 
recommended that women with PPROM 
between 24 and 32 weeks' receive 
corticosteroids to reduce the incidence of IVH. 
Hopefully, obstetricians will use corticosteroids 
more often in the management of preterm labor 
because this treatment may markedly improve 
the quality of survival for many premature 
newborns.
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